Shots:
- Capsigen to receive $15M up front and is eligible to receive up to ~$42M as research milestones and ~$1.25B as additional payments upon the achievement of development and sales milestones along with royalties on net sales of products resulting from the collaboration
- Biogen to get an exclusive license under Capsigen’s technology for CNS and neuromuscular disease targets
- The collaboration leverages Capsigen’s TRADE platform and associated technologies to identify novel AAV capsids with Biogen’s discovery, development, manufacturing and commercialization capabilities to facilitate the delivery of gene therapies for needy patients
Click here to read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Biogen
The post Biogen Collaborates with Capsigen to Discover Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders first appeared on PharmaShots.
